(Q46749977)

24 December 2017

title

Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer (English)

1 reference

24 December 2017

1 reference

1 reference

Gary W Bong

1

1 reference

24 December 2017

Harry S Clarke

series ordinal

2

1 reference

24 December 2017

Wanda C Hancock

series ordinal

3

1 reference

24 December 2017

Thomas E Keane

series ordinal

4

1 reference

24 December 2017

language of work or name

English

0 references

publication date

15 February 2008

1 reference

24 December 2017

published in

Urology

1 reference

24 December 2017

volume

71

1 reference

24 December 2017

issue

6

1 reference

24 December 2017

page(s)

1177-1180

1 reference

24 December 2017

A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Androgen deprivation therapy for prostate cancer: current status and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Intermittent androgen suppression in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Depressed Testosterone Release From Testicular Tissue in Vitro After Withdrawal of Oestrogen Treatment in Patients with Prostatic Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

The Ultrastructural Response of Human Leydig Cells to Exogenous Estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Serum testosterone levels after external beam radiation for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Hypogonadism following prostate-bed radiation therapy for prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Testicular dose in prostate cancer radiotherapy: impact on impairment of fertility and hormonal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Effect of irradiation treatment on gonadal function in men treated for germ cell cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Effects of fractionated irradiation of endocrine aspects of testicular function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.09.066

10.1016/J.UROLOGY.2007.09.066

7 January 2021

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017